Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021)
Keros Therapeutics' (KROS) quarterly Other Non-Current Liabilities came in at $16000.0 in Q3 2021, down 79.22% YoY from $77000.0 in Q3 2020, and down 50.0% on a QoQ basis from $32000.0 in Q2 2021.
Keros Therapeutics (KROS) Other Non-Current Liabilities (2019 - 2021) Analysis & Trends
Keros Therapeutics (KROS) has 3 years of Other Non-Current Liabilities data on file, last reported at $16000.0 in Q3 2021.
- Quarterly Other Non-Current Liabilities fell 79.22% year-over-year to $16000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $16000.0 (down 79.22% YoY) and the FY2020 annual result came in at $62000.0, down 47.9% from the prior year.
- Other Non-Current Liabilities retreated to $16000.0 in Q3 2021, from $32000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $119000.0 in Q4 2019 to a low of $16000.0 in Q3 2021.
- A 3-year average of $68500.0 and a median of $69500.0 in 2020 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2020 — Other Non-Current Liabilities tumbled 47.9% — and 2021, when it sank 79.22%.
- Tracing KROS's Other Non-Current Liabilities over 3 years: stood at $119000.0 in 2019, then sank by 47.9% to $62000.0 in 2020, then slumped by 74.19% to $16000.0 in 2021.
- The last three Other Non-Current Liabilities figures came in at $16000.0 (Q3 2021), $32000.0 (Q2 2021), and $47000.0 (Q1 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 16,000.00 |
| Jun 30, 2021 | 32,000.00 |
| Mar 31, 2021 | 47,000.00 |
| Dec 31, 2020 | 62,000.00 |
| Sep 30, 2020 | 77,000.00 |
| Jun 30, 2020 | 91,000.00 |
| Mar 31, 2020 | 104,000.00 |
| Dec 31, 2019 | 119,000.00 |